Tags

Type your tag names separated by a space and hit enter

Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial.
J Clin Psychiatry. 2015 08; 76(8):e1015-22.JC

Abstract

OBJECTIVE

Docosahexaenoic acid (DHA) might help prevent or attenuate posttraumatic stress disorder (PTSD) symptoms. We examined the efficacy and safety of DHA for preventing PTSD (DSM-IV) after severe accidental injury.

METHOD

From December 2008 to August 2013, we conducted a randomized, double-blind, placebo-controlled trial of 110 accident-injured patients consecutively admitted to an intensive care unit of the National Disaster Medical Center in Tokyo, Japan. All patients were taught about their psychological reactions to accidental injury for 20 minutes and were randomly assigned to receive 1,470 mg/d of DHA plus 147 mg/d of eicosapentaenoic acid (EPA; n = 53) or placebo (n = 57) for 12 weeks. The primary outcome was total score on the Clinician-Administered PTSD Scale (CAPS) at 3-month follow-up. Secondary outcomes included PTSD diagnosis (full-blown or partial PTSD). Adherence to the interventions was assessed by erythrocyte fatty acid composition.

RESULTS

At 3 months, the CAPS total score revealed no differences between the 2 groups (10.78 in the DHA group vs 9.22 in the placebo group; n = 100; P = .572). We found that 11.1% of the DHA group and 5.5% of the placebo group developed PTSD. The erythrocyte level of DHA and EPA in the DHA group was significantly elevated compared to the placebo group (P < .01).

CONCLUSIONS

Docosahexaenoic acid supplementation was not superior to placebo for the secondary prevention of PTSD symptoms at 3 months after severe accidental injury. The efficacy of a different ratio of DHA and EPA and higher doses of omega-3 fatty acids as secondary prevention of PTSD remains to be determined.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT00671099.

Authors+Show Affiliations

Department of Psychiatry, National Disaster Medical Center, 3256 Midoricho, Tachikawa, Tokyo 190-0014, Japan matsuoka-psy@umin.ac.jp.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26335087

Citation

Matsuoka, Yutaka, et al. "Docosahexaenoic Acid for Selective Prevention of Posttraumatic Stress Disorder Among Severely Injured Patients: a Randomized, Placebo-controlled Trial." The Journal of Clinical Psychiatry, vol. 76, no. 8, 2015, pp. e1015-22.
Matsuoka Y, Nishi D, Hamazaki K, et al. Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial. J Clin Psychiatry. 2015;76(8):e1015-22.
Matsuoka, Y., Nishi, D., Hamazaki, K., Yonemoto, N., Matsumura, K., Noguchi, H., Hashimoto, K., & Hamazaki, T. (2015). Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial. The Journal of Clinical Psychiatry, 76(8), e1015-22. https://doi.org/10.4088/JCP.14m09260
Matsuoka Y, et al. Docosahexaenoic Acid for Selective Prevention of Posttraumatic Stress Disorder Among Severely Injured Patients: a Randomized, Placebo-controlled Trial. J Clin Psychiatry. 2015;76(8):e1015-22. PubMed PMID: 26335087.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial. AU - Matsuoka,Yutaka, AU - Nishi,Daisuke, AU - Hamazaki,Kei, AU - Yonemoto,Naohiro, AU - Matsumura,Kenta, AU - Noguchi,Hiroko, AU - Hashimoto,Kenji, AU - Hamazaki,Tomohito, PY - 2014/05/19/received PY - 2014/09/03/accepted PY - 2015/9/4/entrez PY - 2015/9/4/pubmed PY - 2015/12/15/medline SP - e1015 EP - 22 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 76 IS - 8 N2 - OBJECTIVE: Docosahexaenoic acid (DHA) might help prevent or attenuate posttraumatic stress disorder (PTSD) symptoms. We examined the efficacy and safety of DHA for preventing PTSD (DSM-IV) after severe accidental injury. METHOD: From December 2008 to August 2013, we conducted a randomized, double-blind, placebo-controlled trial of 110 accident-injured patients consecutively admitted to an intensive care unit of the National Disaster Medical Center in Tokyo, Japan. All patients were taught about their psychological reactions to accidental injury for 20 minutes and were randomly assigned to receive 1,470 mg/d of DHA plus 147 mg/d of eicosapentaenoic acid (EPA; n = 53) or placebo (n = 57) for 12 weeks. The primary outcome was total score on the Clinician-Administered PTSD Scale (CAPS) at 3-month follow-up. Secondary outcomes included PTSD diagnosis (full-blown or partial PTSD). Adherence to the interventions was assessed by erythrocyte fatty acid composition. RESULTS: At 3 months, the CAPS total score revealed no differences between the 2 groups (10.78 in the DHA group vs 9.22 in the placebo group; n = 100; P = .572). We found that 11.1% of the DHA group and 5.5% of the placebo group developed PTSD. The erythrocyte level of DHA and EPA in the DHA group was significantly elevated compared to the placebo group (P < .01). CONCLUSIONS: Docosahexaenoic acid supplementation was not superior to placebo for the secondary prevention of PTSD symptoms at 3 months after severe accidental injury. The efficacy of a different ratio of DHA and EPA and higher doses of omega-3 fatty acids as secondary prevention of PTSD remains to be determined. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00671099. SN - 1555-2101 UR - https://www.unboundmedicine.com/medline/citation/26335087/Docosahexaenoic_acid_for_selective_prevention_of_posttraumatic_stress_disorder_among_severely_injured_patients:_a_randomized_placebo_controlled_trial_ L2 - http://www.psychiatrist.com/jcp/article/pages/2015/v76n08/v76n0804.aspx DB - PRIME DP - Unbound Medicine ER -